Kiniksa Pharmaceuticals International (KNSA) Share-based Compensation (2017 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Share-based Compensation came in at $11.6 million in Q2 2026, up 31.1% YoY from $8.9 million in Q2 2025, and up 15.71% on a QoQ basis from $10.1 million in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) Share-based Compensation (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 10 years of Share-based Compensation data on file, last reported at $11.6 million in Q2 2026.
- Quarterly Share-based Compensation rose 31.1% year-over-year to $11.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $40.8 million (up 24.6% YoY) and the FY2025 annual result came in at $90.4 million, up 138.39% from the prior year.
- Share-based Compensation advanced to $11.6 million in Q2 2026, from $10.1 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $99.1 million in Q3 2025 to a low of -$178000.0 in Q2 2024.
- A 5-year average of $10.9 million and a median of $7.3 million in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2024 — Share-based Compensation plunged 212.66% — and 2025, when it jumped 5086.52%.
- Tracing KNSA's Share-based Compensation over 5 years: stood at $6.4 million in 2022, then advanced by 21.99% to $7.8 million in 2023, then rose by 6.75% to $8.3 million in 2024, then advanced by 23.34% to $10.2 million in 2025, then advanced by 13.69% to $11.6 million in 2026.
- The last three Share-based Compensation figures came in at $11.6 million (Q2 2026), $10.1 million (Q1 2026), and $10.2 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Kiniksa Pharmaceuticals International | 6.04 Bn | 5.52 Bn | 220.03 Mn | 11.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.64 Mn |
| Jun 30, 2026 | 11.64 Mn |
| Mar 31, 2026 | 10.06 Mn |
| Mar 31, 2026 | 10.06 Mn |
| Dec 31, 2025 | 10.24 Mn |
| Dec 31, 2025 | 10.24 Mn |
| Sep 30, 2025 | 99.14 Mn |
| Sep 30, 2025 | 99.14 Mn |
| Jun 30, 2025 | 8.88 Mn |
| Jun 30, 2025 | 8.88 Mn |
| Mar 31, 2025 | 7.75 Mn |
| Mar 31, 2025 | 7.75 Mn |
| Dec 31, 2024 | 8.30 Mn |
| Dec 31, 2024 | 8.30 Mn |
| Sep 30, 2024 | 7.83 Mn |
| Sep 30, 2024 | 7.83 Mn |
| Jun 30, 2024 | -178,000.00 |
| Jun 30, 2024 | -178,000.00 |
| Mar 31, 2024 | 3.61 Mn |
| Mar 31, 2024 | 3.61 Mn |